Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2013 | 12-2012 | 12-2011 | 12-2010 | 12-2009 | |
| Sales | 25,806,000 | 27,973,000 | 33,591,000 | 33,269,000 | 32,804,000 |
| Cost of Goods | 5,261,000 | 5,393,000 | 6,026,000 | 6,389,000 | 5,775,000 |
| Gross Profit | 20,545,000 | 22,580,000 | 27,565,000 | 26,880,000 | 27,029,000 |
| Operating Expenses | 16,833,000 | 14,432,000 | 14,770,000 | 15,386,000 | 15,486,000 |
| Operating Income | 3,712,000 | 8,148,000 | 12,795,000 | 11,494,000 | 11,543,000 |
| Interest Expense | 495,000 | 544,000 | 562,000 | 1,033,000 | 0 |
| Other Income | 50,000 | 42,000 | 50,000 | 516,000 | -736,000 |
| Pre-tax Income | 3,267,000 | 7,646,000 | 12,283,000 | 10,977,000 | 10,807,000 |
| Income Tax | 696,000 | 1,376,000 | 2,333,000 | 2,896,000 | 3,263,000 |
| Net Income Continuous | 2,571,000 | 6,270,000 | 9,950,000 | 8,081,000 | 7,544,000 |
| Minority Interests | 15,000 | 30,000 | 33,000 | 28,000 | N/A |
| Net Income | $2,556,000 | $6,240,000 | $9,917,000 | $8,053,000 | $7,544,000 |
| EPS Basic Total Ops | 1.02 | 2.48 | 3.65 | 2.80 | 2.60 |
| EPS Basic Continuous Ops | 1.03 | 2.49 | 3.66 | 2.81 | 2.61 |
| EPS Diluted Total Ops | 1.02 | 2.47 | 3.63 | 2.79 | 2.60 |
| EPS Diluted Continuous Ops | 1.03 | 2.48 | 3.64 | 2.79 | 2.60 |
| EBITDA(a) | $8,295,000 | $10,666,000 | $15,345,000 | $14,235,000 | $13,630,000 |